Daniel Wintner  Goodman net worth and biography

Daniel Goodman Biography and Net Worth

Dr. Goodman is a psychiatrist and scientist entrepreneur. Dr. Goodman was co-founder and CEO of PsychoGenics, a leading preclinical neuropharmacology company that combines its in vivo behavioral expertise with robotics, computer vision, and bio/cheminformatics to evaluate drug candidates for utility across the spectrum of neuropsychiatric disease indications. Using its unique technology platform, PsychoGenics identifies new therapeutic potentials for novel, discontinued and early stage compounds. Dr. Goodman was also co-founder and President of Resolvyx Pharmaceuticals, a biopharmaceutical company dedicated to the discovery, development and commercialization of resolvins, a novel class of therapies to treat inflammatory diseases. Dr. Goodman's ongoing research interests span a broad spectrum, from the design and development of novel small molecule compounds for neuropsychiatric and inflammatory diseases to the repurposing of existing drugs for new neuropsychiatric indications. In addition to his scientific interests, Dr. Goodman is a practicing physician with a private psychiatry and psychopharmacology practice in New York and Greenwich, CT, where he treats patients with cognitive, mood, and anxiety disorders. Dr. Goodman also maintains an academic appointment as a clinical assistant professor in the Psychiatry Department at Cornell University Medical College, where he teaches medical students, residents and fellows.

He is a graduate of Yale College, Cambridge University, which he attended as a Churchill Fellow, Harvard Medical School, and Columbia Business School.

What is Daniel Wintner Goodman's net worth?

The estimated net worth of Daniel Wintner Goodman is at least $3.55 as of May 25th, 2021. Mr. Goodman owns 25 shares of Tonix Pharmaceuticals stock worth more than $4 as of November 5th. This net worth approximation does not reflect any other investments that Mr. Goodman may own. Learn More about Daniel Wintner Goodman's net worth.

How do I contact Daniel Wintner Goodman?

The corporate mailing address for Mr. Goodman and other Tonix Pharmaceuticals executives is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. Tonix Pharmaceuticals can also be reached via phone at (862) 799-8599 and via email at [email protected]. Learn More on Daniel Wintner Goodman's contact information.

Has Daniel Wintner Goodman been buying or selling shares of Tonix Pharmaceuticals?

Daniel Wintner Goodman has not been actively trading shares of Tonix Pharmaceuticals over the course of the past ninety days. Most recently, on Tuesday, May 25th, Daniel Wintner Goodman bought 25 shares of Tonix Pharmaceuticals stock. The stock was acquired at an average cost of $224.00 per share, with a total value of $5,600.00. Following the completion of the transaction, the director now directly owns 25 shares of the company's stock, valued at $5,600. Learn More on Daniel Wintner Goodman's trading history.

Who are Tonix Pharmaceuticals' active insiders?

Tonix Pharmaceuticals' insider roster includes Daniel Goodman (Director), and Seth Lederman (CEO). Learn More on Tonix Pharmaceuticals' active insiders.

Daniel Wintner Goodman Insider Trading History at Tonix Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/25/2021Buy25$224.00$5,600.0025View SEC Filing Icon  
See Full Table

Daniel Wintner Goodman Buying and Selling Activity at Tonix Pharmaceuticals

This chart shows Daniel Wintner Goodman's buying and selling at Tonix Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Tonix Pharmaceuticals Company Overview

Tonix Pharmaceuticals logo
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
Read More

Today's Range

Now: $0.14
Low: $0.14
High: $0.15

50 Day Range

MA: $0.17
Low: $0.13
High: $0.37

2 Week Range

Now: $0.14
Low: $0.12
High: $22.14

Volume

14,407,403 shs

Average Volume

10,123,260 shs

Market Capitalization

$19.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.06